Takeda Pharmaceutical (NYSE:TAK) Issues FY 2024 Earnings Guidance

Takeda Pharmaceutical (NYSE:TAK) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 3.330-3.330 for the period. The company issued revenue guidance of $30.1 billion-$30.1 billion.

Takeda Pharmaceutical Stock Up 2.5 %

Takeda Pharmaceutical stock traded up $0.34 during midday trading on Thursday, reaching $13.65. The company’s stock had a trading volume of 1,077,594 shares, compared to its average volume of 1,952,328. Takeda Pharmaceutical has a fifty-two week low of $12.57 and a fifty-two week high of $15.08. The company has a quick ratio of 0.77, a current ratio of 1.28 and a debt-to-equity ratio of 0.64. The company has a market cap of $43.42 billion, a P/E ratio of 23.54, a P/E/G ratio of 0.24 and a beta of 0.51. The business has a 50-day simple moving average of $13.30 and a 200-day simple moving average of $13.89.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 10.00% and a net margin of 6.49%. On average, research analysts expect that Takeda Pharmaceutical will post 1.55 earnings per share for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.